Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia presenting with extramedullary disease. The study reported an overall response rate of 54%, with 43.5% of patients achieving complete remission (CR) or CR with incomplete hematologic recovery (CRi). However, the responses were not durable, and relapse occurred in 60% of those who achieved CR/CRi, highlighting the need for additional therapies such as allogeneic stem cell transplantation to maintain disease control.